Richard A. Furie, MD, discussed the challenges in managing antiphospholipid syndrome at the 2024 Congress of Clinical Rheumatology West. He highlighted the difficulties in preventing the first thrombosis and better preventing the second. Prophylactic aspirin has shown inadequacies, and warfarin is burdensome for patients. Furie suggested complement inhibition as an alternative treatment. Conducting research in this area is challenging due to the low event rate of thrombosis. Furie emphasized the need for primary and secondary prevention therapy in antiphospholipid syndrome and warned that it is more common than perceived. He also discussed the challenges of studying this syndrome.
Source link
Preventing first thrombosis remains top unmet need in antiphospholipid syndrome
